All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

FDA grants approval to brentuximab vedotin for frontline PTCL

Nov 19, 2018


On 18 November 2018, brentuximab vedotin in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, and prednisone) was granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified. This approval comes after brentuximab vedotin was granted Breakthrough Therapy Designation on 16 November 2018.

The approval granted by the FDA was based on the positive results obtained from the multi-center, randomized, double-blind, placebo-controlled phase III ECHELON-2 trial (NCT01777152) assessing brentuximab vedotin in combination with CHP versus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) alone, as a frontline therapy in patients with CD30-expressing PTCL.

The phase III ECHELON-2 study met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS) of brentuximab vedotin in combination with CHP versus CHOP as assessed by a Blinded Independent Central Review facility (BICR, HR = 0.71, 95% CI, 0.54–0.93, P = 0.011), corresponding to a 29% reduction in the risk of progression, death, or treatment of residual or progressive disease. In addition, brentuximab vedotin plus CHP led to a superior overall survival compared to standard CHOP chemotherapy (HR = 0.66, 95% CI, 0.46–0.95, P = 0.024) in the treatment of CD30-expressing PTCL. The results of the phase III ECHELON-2 study will be presented at the American Society of Hematology (ASH) 2018 Annual Meeting.

According to the drug manufacturers, the FDA, approved brentuximab vedotin via a new review program, Real-Time Oncology Review Pilot Program, which occurred less than two weeks from the date that the complete application was submitted.

References

Your opinion matters

What types of support services or resources do you think would best facilitate the safe implementation of the BrECADD regimen in clinical practice?